Results 91 to 100 of about 3,166 (218)

Second-Generation Live-Attenuated Candid#1 Vaccine Virus Resists Reversion and Protects against Lethal Junín Virus Infection in Guinea Pigs. [PDF]

J Virol, 2021
Gowen BB, Hickerson BT, York J, Westover JB, Sefing EJ, Bailey KW, Wandersee L, Nunberg JH.   +7 more
europepmc   +1 more source

Viral hemorrhagic fevers, Junin virus, Lassa virus, Lujo virus: (Week 15) Weekly cases* of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents week ending April 17, 2021

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Viral hemorrhagic fevers; Junin virus, Lassa virus, Lujo virus cases.

core  

Viral hemorrhagic fevers, Junin virus, Lassa virus, Lujo virus: (Week 33) Weekly cases* of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents week ending August 20, 2022

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Viral hemorrhagic fevers; Junin virus, Lassa virus, Lujo virus cases.

core  

A review of emerging health threats from zoonotic New World mammarenaviruses

BMC Microbiology
Despite repeated spillover transmission and their potential to cause significant morbidity and mortality in human hosts, the New World mammarenaviruses remain largely understudied.
Arianna Lendino, Adrian A. Castellanos, David M. Pigott, Barbara A. Han   +3 more
doaj   +1 more source

Viral hemorrhagic fevers, Junin virus, Lassa virus, Lujo virus: (Week 48) Weekly cases* of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents week ending December 3, 2022

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Viral hemorrhagic fevers; Junin virus, Lassa virus, Lujo virus cases.

core  

Bovine Serum Albumin Nanoparticle-Mediated Delivery of Ribavirin and Mycophenolic Acid for Enhanced Antiviral Therapeutics

Viruses
The global spread of viral diseases is a public health issue. Ribavirin (RBV) and mycophenolic acid (MPA) are well-known wide-spectrum antiviral agents.
Mayra A. Castañeda Cataña, Andrea P. Rivas Marquina, Martín M. Dodes Traian, M. Josefina Carlucci, Elsa B. Damonte, Oscar E. Pérez, Eva C. Arrua, Claudia S. Sepúlveda   +7 more
doaj   +1 more source

Viral hemorrhagic fevers, Junin virus, Lassa virus, Lujo virus: (Week 34) Weekly cases* of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents week ending August 28, 2021

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Viral hemorrhagic fevers; Junin virus, Lassa virus, Lujo virus cases.

core  

[Immunopathology induced in the rat by Junin virus].

Revista Argentina de microbiologia, 1991
Intra-cerebral infection of the 10-day-old rat with the XJ prototype strain of Junin virus induces an immunopathological encephalitis with 100% mortality. In contrast with previous observations, our present work with antithymocyte serum (ATS) demonstrates a pathological role for the cellular immune response in this experimental model.
M C, Remesar, J L, Blejer, M R, Nejamkis
openaire   +1 more source

Viral hemorrhagic fevers, Junin virus, Lassa virus, Lujo virus: (Week 7) Weekly cases* of notifiable diseases, United States, U.S. territories, and Non-U.S. Residents week ending February 19, 2022

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering Viral hemorrhagic fevers; Junin virus, Lassa virus, Lujo virus cases.

core  

Multi-epitope-based vaccine designing against Junín virus glycoprotein: immunoinformatics approach

Future Journal of Pharmaceutical Sciences
Background The Junín virus (JUNV) is well known for causing argentine haemorrhagic fever (AHF), a severe endemic disease in farming premises. The glycoprotein of JUNV is an important therapeutic target in vaccine design.
Mallari Praveen
doaj   +1 more source